Objective:To investigate the current situation of using letrozole tablets in male patients in our hospital and conduct evidence-based evaluation to promote the rational use of aromatase inhibitors such as letrozole in male patients.Methods:A total of 153 prescriptions for letrozole used by male patients in our hospital from August 2017 to August 2022 were selected,and the types of drug use beyond the in-structions were classified.The evaluation results were graded according to the evidence recommendations in the Evidence Based Evaluation of Drug Use beyond the Instructions.Results:The proportions of drug use beyond indications,drug use beyond suitable populations and drug use beyond dose and frequency were 90.51%,6.33%and 3.16%,respectively.Evidence-based evaluation was conducted on 11 types of medica-tion beyond specification,among which 1,2,2 and 6 types were valued as Class A,B,C and not recom-mended,respectively.Conclusion:Letrozole is effective in the treatment of male breast cancer,male infer-tility and male hypogonadism.Routine use is not recommended for varicocele,azoospermia or male breast development,and options may be considered when there are no alternatives.For prostatitis/prostatic hyper-trophy/epididymitis,cavernous sclerosis of penis,erectile dysfunction in men and oestrogen overproduction,letrozole is not recommended.
关键词
来曲唑/芳香化酶抑制剂/男性/超说明书/循证评价
Key words
Letrozole/Aromatase inhibitors/Male/Exceeding the specification/Evidence-based review
维普
万方数据